Gene Therapy Market Size 2024-2028
The gene therapy market size is forecast to increase by USD 6.74 billion, at a CAGR of 23.31% between 2023 and 2028.
- The market is experiencing significant growth, driven by the increasing number of special drug designations granted to gene therapy products. This trend signifies regulatory approval and validation of gene therapy as a viable treatment modality, encouraging further investment and innovation. Another key driver is the expanding research in gene therapy applications for cardiovascular diseases (CVDs) and orphan diseases, which hold immense potential for addressing unmet medical needs and improving patient outcomes. Its applications span diverse fields, including ophthalmology in Japan, where vision-restoring treatments are gaining traction, and infectious disease research in Asia, addressing global health challenges.
- Companies must navigate this obstacle by exploring cost reduction strategies, collaborating with payers and insurers, and demonstrating the long-term value of these therapies to secure reimbursement and patient access. Effective management of these challenges, alongside continued innovation and regulatory support, will enable market players to capitalize on the promising opportunities in the market.
What will be the Size of the Gene Therapy Market during the forecast period?
Explore in-depth regional segment analysis with market size data - historical 2018-2022 and forecasts 2024-2028 - in the full report.
Request Free Sample
The market continues to evolve, driven by advancements in various sectors. Gene replacement therapies, utilizing viral vectors to deliver functional genes, are gaining traction in the treatment of genetic disorders. Gene silencing, a modality that manipulates the expression of mutated genes, is also making strides in healthcare, particularly for chronic conditions. The therapeutic areas spanning from neurology indications to orphan diseases are witnessing significant progress. Gene therapy's mechanism of action, which can include gene augmentation, molecular carriers, and advanced targeted therapies, is revolutionizing precision medicine. Startup companies and biotechnology firms are spearheading innovation, developing delivery systems and preclinical testing for gene therapy products.
Regulatory approval processes, including drug designations and patent portfolio strength, are adapting to accommodate these emerging technologies. Advanced technologies, such as hybrid vector systems and non-viral vectors, are extending the shelf life and commercialization strategies of gene therapy products. Big pharma players are increasingly investing in gene editing therapies, further fueling market growth. Clinical research initiatives, including clinical trials and investment funding, are paving the way for the development of new gene therapy products. Gene therapy's role in cancer treatment and genome sequencing is also expanding, reflecting the vast potential of this dynamic field. The regulatory landscape is evolving to accommodate these medical advancements, with regulatory approval processes becoming more streamlined.
Temperature control and route of administration are crucial considerations in the development of gene therapy products. In the genomics field, gene therapy is playing a pivotal role in the manipulation of genes and biological therapies, leading to therapeutic innovation and improved patient outcomes. The market is a continually unfolding landscape, with ongoing research and development initiatives shaping its future.
How is this Gene Therapy Industry segmented?
The gene therapy industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD million" for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.
- Delivery Mode
- Therapy Area
- Oncology
- CNS
- Ophthalmology
- Rare diseases
- Others
- Vector Type
- Viral Vectors
- Non-viral Vectors
- Indication
- Genetic Disorders
- Cancer
- Infectious Diseases
- Application
- Oncology
- Orphan Diseases
- Neurological Disorders
- Cardiovascular Diseases
- Infectious Diseases
- Hematological Disorders
- Geography
- North America
- Europe
- Middle East and Africa
- APAC
- South America
- Rest of World (ROW)
By Delivery Mode Insights
The in vivo segment is estimated to witness significant growth during the forecast period.
In the realm of medical innovation, in vivo gene therapy represents a groundbreaking technique that delivers genetic material directly into target cells to effect therapeutic change. This approach, which employs various vectors to transfer functional genes into cells, has gained significant traction in numerous scientific fields. Approved gene therapies now incorporate this method to address faulty or absent genes, such as those linked to rare diseases or chronic conditions. The market is marked by continuous advancements in gene delivery techniques, including viral vectors and non-viral carriers. The regulatory landscape is evolving to accommodate these advanced therapies, with regulatory approvals paving the way for commercialization.
Big pharma players and biotechnology firms are investing heavily in gene therapy research, particularly in neurology indications and oncolytic viral therapy. In the genomic field, precision medicine and gene editing modalities are driving innovation, with emerging technologies like CRISPR-Cas9 and RNA interference (RNAi) gaining significant attention. Startup companies and academic institutions are also contributing to the clinical pipeline through preclinical testing and clinical research initiatives. Gene therapy products, including gene augmentation, gene replacement, and cell replacement therapies, are showing promising treatment efficacy for various therapeutic areas, such as genetic disorders and orphan diseases. The market is further enriched by advanced targeted therapies and molecular switches, which offer personalized treatment options.
As the market continues to evolve, temperature control, shelf life, and commercialization strategies become increasingly important considerations. Biological therapies and gene editing therapies, including hybrid vector systems and vector selection, are also key factors influencing patient outcomes and capital investments. In conclusion, in vivo gene therapy is a dynamic and evolving field that holds immense potential for transforming the lives of patients suffering from a range of diseases and disorders. With continued advancements in gene delivery methods, regulatory approval, and scientific understanding, this innovative approach to medicine is poised to make a significant impact on healthcare and the lives of those in need.
Request Free Sample
The In vivo segment was valued at USD 1.31 billion in 2018 and showed a gradual increase during the forecast period.
Regional Analysis
North America is estimated to contribute 40% to the growth of the global market during the forecast period.Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.
Request Free Sample
The market is experiencing significant growth, particularly in North America, driven by substantial research and development investments, especially in the US. With hundreds of clinical trials underway in the region, primarily focusing on cancer, HIV/AIDS, and cardiovascular diseases, the market holds immense potential. The prevalence of these conditions, such as the high incidence of various types of cancers, has led to a substantial demand for innovative treatments. Gene therapy, which includes gene silencing, gene replacement, gene augmentation, and gene editing modalities, is a promising area of medical advancement. Biotechnology firms and big pharma players are investing heavily in gene therapy products, leveraging advanced technologies like viral vectors, molecular carriers, and hybrid vector systems.
The regulatory landscape is evolving, with regulatory approvals for gene therapies increasing, enabling commercialization strategies for these innovative treatments. The market encompasses various therapeutic areas, including neurology indications and genetic disorders, and offers potential for cell replacement, precision medicine, and advanced targeted therapies. The market's success relies on preclinical testing, clinical studies, and investment funding to bring these therapies to market. Gene therapy products, such as gene editing therapies and marketed gene therapies, are expected to significantly impact patient outcomes, particularly in chronic conditions. Temperature control and shelf life are critical considerations for these biological therapies.
The market is a dynamic and evolving landscape, with emerging technologies, such as molecular switches and non-viral vectors, poised to make a significant impact.
Market Dynamics
Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
The Gene Therapy Market is advancing rapidly, with viral vector gene therapies, CAR-T cell therapies, and CRISPR-based therapies revolutionizing healthcare. AAV-based gene therapies target cancer treatment and rare disease treatment, leveraging CRISPR-Cas9 gene editing and lipid nanoparticles for precision. Personalized gene therapies address individual needs, driving growth in the oncology gene therapy market. High-demand searches like best gene therapy for cancer treatment 2025, top CRISPR-based therapies for rare diseases, and best AAV-based gene therapies for neurological disorders reflect patient interest. How to access affordable gene therapies, gene therapy for spinal muscular atrophy benefits, and top CAR-T cell therapies for leukemia guide choices. Non-viral gene therapies for cardiovascular diseases, best gene therapy clinics in USA 2025, how to choose safe gene therapy treatments, and advances in CRISPR-Cas9 gene editing 2025 shape the market's future.
What are the key market drivers leading to the rise in the adoption of Gene Therapy Industry?
- The significant growth in the number of special drug designations is the primary factor fueling market expansion. This designation process, overseen by regulatory authorities, acknowledges a drug's ability to address unmet medical needs, thereby increasing its market potential.
- Gene therapy, a revolutionary approach in healthcare, is gaining significant traction in the treatment of rare diseases and chronic conditions. This field, driven by advancements in gene silencing technologies, precision medicine, and manipulation technologies, is transforming the way we approach disease indications. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA), have granted numerous designations, such as orphan drug designation, fast track designation, and breakthrough designation, to gene therapy programs. These designations offer pharmaceutical companies ten years of market exclusivity, tax benefits, and expedited regulatory approval processes. The clinical pipeline in the market is robust, with a focus on disease areas like metachromatic leukodystrophy and oncolytic viral therapy.
- The patent portfolio strength in the genomics field is another factor fueling the growth of this market. The regulatory landscape is evolving to accommodate the unique challenges of gene therapy, with a focus on safety and efficacy. The route of administration for gene therapy is diverse, ranging from viral vectors to direct injection, offering flexibility in treatment options. Clinical research initiatives continue to drive innovation in gene therapy, with the potential to revolutionize healthcare costs and improve patient outcomes.
What are the market trends shaping the Gene Therapy Industry?
- The emerging field of gene therapy is gaining significant attention in the medical community for its potential applications in cardiovascular diseases and orphan conditions. Growing research and development efforts in this area represent the latest market trends.
- Gene therapy, a form of molecular medicine, has gained significant attention in the healthcare industry due to its potential to treat various genetic disorders and diseases. This advanced therapeutic approach involves the use of viral vectors to deliver healthy genes into cells, enabling gene replacement or gene augmentation. The therapeutic areas for gene therapy span across numerous conditions, including neurology indications, oncology, and orphan diseases. The mechanism of action for gene therapy is based on the introduction of functional genes into target cells, thereby restoring or enhancing the production of missing or defective proteins. The development of innovative gene therapy treatments is driven by the need for more effective and targeted therapies, particularly in areas where traditional treatments have limitations.
- Startup companies and advanced technology players are at the forefront of gene therapy research and development, focusing on the creation of novel delivery systems and gene editing modalities. Preclinical testing plays a crucial role in evaluating the safety and efficacy of these treatments before they can progress to clinical trials. Biological therapies, including gene therapy, are increasingly becoming essential components of the pharmaceutical industry's portfolio, with big pharma players investing heavily in research and development. The emphasis on gene therapy lies in its potential to offer long-term solutions for various diseases, including those with high unmet medical needs.
- Advanced targeted therapies, such as gene therapy, are expected to revolutionize the treatment landscape by providing more personalized and precise interventions. Emerging technologies, including gene editing modalities, are also poised to expand the scope of gene therapy applications. In conclusion, the market is experiencing significant growth due to the increasing prevalence of genetic disorders and diseases, the urgency to develop more effective treatments, and the advancements in technology. The potential of gene therapy to offer targeted, long-term solutions makes it a promising area for investment and innovation.
What challenges does the Gene Therapy Industry face during its growth?
- The high cost of treatment is a significant challenge impeding the growth of the industry.
- Gene therapy, a revolutionary approach to treating genetic disorders, involves introducing functional genes into a patient's cells to replace or supplement defective genes. This innovative treatment modality holds significant promise in addressing various genetic conditions. However, the market for gene therapy faces several challenges, including the high cost of manufacturing and clinical trials. The cost of gene therapies ranges from USD300,000 to USD1,200,000, primarily due to the need for personalized treatment and intensive clinical studies. Gene therapy's delivery platforms vary, with viral vectors being the most common method. These vectors, such as adeno-associated viruses (AAV), are used to introduce the modified gene into the patient's cells.
- Temperature control during storage and transportation is crucial to ensure the shelf life and efficacy of gene therapies. Biotechnology firms are investing heavily in gene editing therapies, with a focus on target therapeutic areas like genetic disorders, cancer, and inherited diseases. Clinical studies are underway to evaluate the safety and efficacy of these therapies, with regulatory approval being a significant hurdle. Gene therapy's molecular switches and gene modification techniques offer immense potential in treating various conditions. Cell replacement therapy is another area where gene therapy shows promise. Despite the challenges, the market continues to grow, driven by advancements in genomic research and gene modification technologies.
Exclusive Customer Landscape
The gene therapy market forecasting report includes the adoption lifecycle of the market, covering from the innovator's stage to the laggard's stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the gene therapy market report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.
Customer Landscape
Key Companies & Market Insights
Companies are implementing various strategies, such as strategic alliances, gene therapy market forecast, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the industry.
Astellas Pharma Inc. - The company specializes in gene therapy innovations, including the Phase 3 VIITAL Clinical Trial of EB 101. This advanced therapeutic approach harnesses the power of genes to address various health conditions. EB 101, a specific gene therapy solution under development, is currently in the late-stage clinical trial phase. This trial signifies a significant step forward in the scientific community's pursuit of effective, gene-based treatments. The company's commitment to research and development drives its mission to transform lives through groundbreaking gene therapies.
The industry research and growth report includes detailed analyses of the competitive landscape of the market and information about key companies, including:
- Astellas Pharma Inc.
- bluebird bio, Inc.
- CRISPR Therapeutics AG
- Gilead Sciences, Inc.
- Kite Pharma (Gilead Sciences)
- Novartis AG
- Orchard Therapeutics plc
- Pfizer Inc.
- RegenXBio Inc.
- Roche Holding AG
- Sarepta Therapeutics, Inc.
- Spark Therapeutics (Roche)
- uniQure N.V.
- Voyager Therapeutics, Inc.
- VBL Therapeutics
- Vertex Pharmaceuticals Incorporated
- Xencor, Inc.
- Sangamo Therapeutics, Inc.
- Amgen Inc.
- Biogen Inc.
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key industry players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
Recent Development and News in Gene Therapy Market
- In January 2024, Spark Therapeutics, a leading gene therapy company, announced the US Food and Drug Administration (FDA) approval of its gene therapy, Zynteglo, for the treatment of transfusion-dependent ?-thalassemia. This marked the third gene therapy approval for the company and further solidified its position in the market (Spark Therapeutics, 2024).
- In March 2024, Merck KGaA and CRISPR Therapeutics entered into a strategic collaboration to develop and commercialize CRISPR-based gene-editing therapies. This partnership combined Merck's commercial capabilities with CRISPR's gene-editing technology, aiming to bring innovative treatments to patients (Merck KGaA, 2024).
- In April 2025, Editas Medicine raised USD150 million in a Series C funding round, led by new investor OrbiMed. The funds will support the development of the company's gene editing platform and its pipeline of potential gene therapy treatments (Editas Medicine, 2025).
- In May 2025, the European Commission granted marketing authorization for Novartis' gene therapy, Zolgensma, for the treatment of spinal muscular atrophy in patients under two years of age. This approval expanded the reach of the therapy, which was already approved in the US, to European patients (Novartis, 2025).
Research Analyst Overview
- In the dynamic and evolving the market, traditional medicines are being challenged by innovative treatments based on gene augmentation and editing modalities. Preclinical testing of gene therapy products using viral and non-viral vectors as molecular carriers is underway, with regulatory approval being a crucial milestone. Gene silencing and cell replacement therapies are gaining traction in disease indications such as neurology, with metachromatic leukodystrophy being a notable indication for gene replacement. The clinical pipeline is rich with advanced targeted therapies, including gene therapy for various disease indications, undergoing clinical trials.
- Biological therapies, including gene therapy, require stringent temperature control to ensure shelf life and efficacy. The genomics field continues to drive research initiatives, leading to the development of new gene therapy products and editing modalities. Gene therapy holds promise for treating mutated genes and revolutionizing the healthcare landscape.
Dive into Technavio's robust research methodology, blending expert interviews, extensive data synthesis, and validated models for unparalleled Gene Therapy Market insights. See full methodology.
|
Market Scope
|
|
Report Coverage
|
Details
|
|
Page number
|
177
|
|
Base year
|
2023
|
|
Historic period
|
2018-2022 |
|
Forecast period
|
2024-2028
|
|
Growth momentum & CAGR
|
Accelerate at a CAGR of 23.31%
|
|
Market growth 2024-2028
|
USD 6738 million
|
|
Market structure
|
Fragmented
|
|
YoY growth 2023-2024(%)
|
18.59
|
|
Key countries
|
US, Canada, Germany, UK, Italy, France, China, India, Japan, Brazil, Egypt, UAE, Oman, Argentina, KSA, UAE, Brazil, and Rest of World (ROW)
|
|
Competitive landscape
|
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks
|
Request Free Sample
What are the Key Data Covered in this Gene Therapy Market Research and Growth Report?
- CAGR of the Gene Therapy industry during the forecast period
- Detailed information on factors that will drive the growth and forecasting between 2024 and 2028
- Precise estimation of the size of the market and its contribution of the industry in focus to the parent market
- Accurate predictions about upcoming growth and trends and changes in consumer behaviour
- Growth of the market across North America, Europe, Asia, and Rest of World (ROW)
- Thorough analysis of the market's competitive landscape and detailed information about companies
- Comprehensive analysis of factors that will challenge the gene therapy market growth of industry companies
We can help! Our analysts can customize this gene therapy market research report to meet your requirements.
Get in touch
1 Executive Summary
- 1.1 Market overview
- Executive Summary - Chart on Market Overview
- Executive Summary - Data Table on Market Overview
- Executive Summary - Chart on Global Market Characteristics
- Executive Summary - Chart on Market by Geography
- Executive Summary - Chart on Market Segmentation by Delivery Mode
- Executive Summary - Chart on Market Segmentation by Therapy Area
- Executive Summary - Chart on Incremental Growth
- Executive Summary - Data Table on Incremental Growth
- Executive Summary - Chart on Company Market Positioning
2 Market Landscape
- 2.1 Market ecosystem
- Parent Market
- Data Table on - Parent Market
- 2.2 Market characteristics
- Market characteristics analysis
3 Market Sizing
- 3.1 Market definition
- Offerings of companies included in the market definition
- 3.2 Market segment analysis
- 3.4 Market outlook: Forecast for 2023-2028
- Chart on Global - Market size and forecast 2023-2028 ($ million)
- Data Table on Global - Market size and forecast 2023-2028 ($ million)
- Chart on Global Market: Year-over-year growth 2023-2028 (%)
- Data Table on Global Market: Year-over-year growth 2023-2028 (%)
4 Historic Market Size
- 4.1 Global Gene Therapy Market 2018 - 2022
- Historic Market Size - Data Table on Global Gene Therapy Market 2018 - 2022 ($ million)
- 4.2 Delivery Mode segment analysis 2018 - 2022
- Historic Market Size - Delivery Mode Segment 2018 - 2022 ($ million)
- 4.3 Therapy Area segment analysis 2018 - 2022
- Historic Market Size - Therapy Area Segment 2018 - 2022 ($ million)
- 4.4 Geography segment analysis 2018 - 2022
- Historic Market Size - Geography Segment 2018 - 2022 ($ million)
- 4.5 Country segment analysis 2018 - 2022
- Historic Market Size - Country Segment 2018 - 2022 ($ million)
5 Five Forces Analysis
- 5.1 Five forces summary
- Five forces analysis - Comparison between 2023 and 2028
- 5.2 Bargaining power of buyers
- Bargaining power of buyers - Impact of key factors 2023 and 2028
- 5.3 Bargaining power of suppliers
- Bargaining power of suppliers - Impact of key factors in 2023 and 2028
- 5.4 Threat of new entrants
- Threat of new entrants - Impact of key factors in 2023 and 2028
- 5.5 Threat of substitutes
- Threat of substitutes - Impact of key factors in 2023 and 2028
- 5.6 Threat of rivalry
- Threat of rivalry - Impact of key factors in 2023 and 2028
- 5.7 Market condition
- Chart on Market condition - Five forces 2023 and 2028
6 Market Segmentation by Delivery Mode
- 6.1 Market segments
- Chart on Delivery Mode - Market share (2023-2028) (%)
- Data Table on Delivery Mode - Market share (2023-2028) (%)
- 6.2 Comparison by Delivery Mode
- Chart on Comparison by Delivery Mode
- Data Table on Comparison by Delivery Mode
- 6.3 In vivo - Market size and forecast (2023-2028)
- Chart on In vivo - Market size and forecast (2023-2028) ($ million)
- Data Table on In vivo - Market size and forecast (2023-2028) ($ million)
- Chart on In vivo - Year-over-year growth (2023-2028) (%)
- Data Table on In vivo - Year-over-year growth (2023-2028) (%)
- 6.4 Ex vivo - Market size and forecast (2023-2028)
- Chart on Ex vivo - Market size and forecast (2023-2028) ($ million)
- Data Table on Ex vivo - Market size and forecast (2023-2028) ($ million)
- Chart on Ex vivo - Year-over-year growth (2023-2028) (%)
- Data Table on Ex vivo - Year-over-year growth (2023-2028) (%)
- 6.5 Market opportunity by Delivery Mode
- Market opportunity by Delivery Mode ($ million)
- Data Table on Market opportunity by Delivery Mode ($ million)
7 Market Segmentation by Therapy Area
- 7.1 Market segments
- Chart on Therapy Area - Market share (2023-2028) (%)
- Data Table on Therapy Area - Market share (2023-2028) (%)
- 7.2 Comparison by Therapy Area
- Chart on Comparison by Therapy Area
- Data Table on Comparison by Therapy Area
- 7.3 Oncology - Market size and forecast (2023-2028)
- Chart on Oncology - Market size and forecast (2023-2028) ($ million)
- Data Table on Oncology - Market size and forecast (2023-2028) ($ million)
- Chart on Oncology - Year-over-year growth (2023-2028) (%)
- Data Table on Oncology - Year-over-year growth (2023-2028) (%)
- 7.4 CNS - Market size and forecast (2023-2028)
- Chart on CNS - Market size and forecast (2023-2028) ($ million)
- Data Table on CNS - Market size and forecast (2023-2028) ($ million)
- Chart on CNS - Year-over-year growth (2023-2028) (%)
- Data Table on CNS - Year-over-year growth (2023-2028) (%)
- 7.5 Ophthalmology - Market size and forecast (2023-2028)
- Chart on Ophthalmology - Market size and forecast (2023-2028) ($ million)
- Data Table on Ophthalmology - Market size and forecast (2023-2028) ($ million)
- Chart on Ophthalmology - Year-over-year growth (2023-2028) (%)
- Data Table on Ophthalmology - Year-over-year growth (2023-2028) (%)
- 7.6 Rare diseases - Market size and forecast (2023-2028)
- Chart on Rare diseases - Market size and forecast (2023-2028) ($ million)
- Data Table on Rare diseases - Market size and forecast (2023-2028) ($ million)
- Chart on Rare diseases - Year-over-year growth (2023-2028) (%)
- Data Table on Rare diseases - Year-over-year growth (2023-2028) (%)
- 7.7 Others - Market size and forecast (2023-2028)
- Chart on Others - Market size and forecast (2023-2028) ($ million)
- Data Table on Others - Market size and forecast (2023-2028) ($ million)
- Chart on Others - Year-over-year growth (2023-2028) (%)
- Data Table on Others - Year-over-year growth (2023-2028) (%)
- 7.8 Market opportunity by Therapy Area
- Market opportunity by Therapy Area ($ million)
- Data Table on Market opportunity by Therapy Area ($ million)
8 Market Segmentation by Vector Type
- 8.1 Market segments
- Chart on Vector Type - Market share (2023-2028) (%)
- Data Table on Vector Type - Market share (2023-2028) (%)
- 8.2 Comparison by Vector Type
- Chart on Comparison by Vector Type
- Data Table on Comparison by Vector Type
- 8.3 Viral Vectors - Market size and forecast (2023-2028)
- Chart on Viral Vectors - Market size and forecast (2023-2028) ($ million)
- Data Table on Viral Vectors - Market size and forecast (2023-2028) ($ million)
- Chart on Viral Vectors - Year-over-year growth (2023-2028) (%)
- Data Table on Viral Vectors - Year-over-year growth (2023-2028) (%)
- 8.4 Non-viral Vectors - Market size and forecast (2023-2028)
- Chart on Non-viral Vectors - Market size and forecast (2023-2028) ($ million)
- Data Table on Non-viral Vectors - Market size and forecast (2023-2028) ($ million)
- Chart on Non-viral Vectors - Year-over-year growth (2023-2028) (%)
- Data Table on Non-viral Vectors - Year-over-year growth (2023-2028) (%)
- 8.5 Market opportunity by Vector Type
- Market opportunity by Vector Type ($ million)
- Data Table on Market opportunity by Vector Type ($ million)
9 Market Segmentation by Indication
- 9.1 Market segments
- Chart on Indication - Market share (2023-2028) (%)
- Data Table on Indication - Market share (2023-2028) (%)
- 9.2 Comparison by Indication
- Chart on Comparison by Indication
- Data Table on Comparison by Indication
- 9.3 Genetic Disorders - Market size and forecast (2023-2028)
- Chart on Genetic Disorders - Market size and forecast (2023-2028) ($ million)
- Data Table on Genetic Disorders - Market size and forecast (2023-2028) ($ million)
- Chart on Genetic Disorders - Year-over-year growth (2023-2028) (%)
- Data Table on Genetic Disorders - Year-over-year growth (2023-2028) (%)
- 9.4 Cancer - Market size and forecast (2023-2028)
- Chart on Cancer - Market size and forecast (2023-2028) ($ million)
- Data Table on Cancer - Market size and forecast (2023-2028) ($ million)
- Chart on Cancer - Year-over-year growth (2023-2028) (%)
- Data Table on Cancer - Year-over-year growth (2023-2028) (%)
- 9.5 Infectious Diseases - Market size and forecast (2023-2028)
- Chart on Infectious Diseases - Market size and forecast (2023-2028) ($ million)
- Data Table on Infectious Diseases - Market size and forecast (2023-2028) ($ million)
- Chart on Infectious Diseases - Year-over-year growth (2023-2028) (%)
- Data Table on Infectious Diseases - Year-over-year growth (2023-2028) (%)
- 9.6 Market opportunity by Indication
- Market opportunity by Indication ($ million)
- Data Table on Market opportunity by Indication ($ million)
10 Market Segmentation by Application
- 10.1 Market segments
- Chart on Application - Market share (2023-2028) (%)
- Data Table on Application - Market share (2023-2028) (%)
- 10.2 Comparison by Application
- Chart on Comparison by Application
- Data Table on Comparison by Application
- 10.3 Oncology - Market size and forecast (2023-2028)
- Chart on Oncology - Market size and forecast (2023-2028) ($ million)
- Data Table on Oncology - Market size and forecast (2023-2028) ($ million)
- Chart on Oncology - Year-over-year growth (2023-2028) (%)
- Data Table on Oncology - Year-over-year growth (2023-2028) (%)
- 10.4 Orphan Diseases - Market size and forecast (2023-2028)
- Chart on Orphan Diseases - Market size and forecast (2023-2028) ($ million)
- Data Table on Orphan Diseases - Market size and forecast (2023-2028) ($ million)
- Chart on Orphan Diseases - Year-over-year growth (2023-2028) (%)
- Data Table on Orphan Diseases - Year-over-year growth (2023-2028) (%)
- 10.5 Neurological Disorders - Market size and forecast (2023-2028)
- Chart on Neurological Disorders - Market size and forecast (2023-2028) ($ million)
- Data Table on Neurological Disorders - Market size and forecast (2023-2028) ($ million)
- Chart on Neurological Disorders - Year-over-year growth (2023-2028) (%)
- Data Table on Neurological Disorders - Year-over-year growth (2023-2028) (%)
- 10.6 Cardiovascular Diseases - Market size and forecast (2023-2028)
- Chart on Cardiovascular Diseases - Market size and forecast (2023-2028) ($ million)
- Data Table on Cardiovascular Diseases - Market size and forecast (2023-2028) ($ million)
- Chart on Cardiovascular Diseases - Year-over-year growth (2023-2028) (%)
- Data Table on Cardiovascular Diseases - Year-over-year growth (2023-2028) (%)
- 10.7 Infectious Diseases - Market size and forecast (2023-2028)
- Chart on Infectious Diseases - Market size and forecast (2023-2028) ($ million)
- Data Table on Infectious Diseases - Market size and forecast (2023-2028) ($ million)
- Chart on Infectious Diseases - Year-over-year growth (2023-2028) (%)
- Data Table on Infectious Diseases - Year-over-year growth (2023-2028) (%)
- 10.8 Hematological Disorders - Market size and forecast (2023-2028)
- Chart on Hematological Disorders - Market size and forecast (2023-2028) ($ million)
- Data Table on Hematological Disorders - Market size and forecast (2023-2028) ($ million)
- Chart on Hematological Disorders - Year-over-year growth (2023-2028) (%)
- Data Table on Hematological Disorders - Year-over-year growth (2023-2028) (%)
- 10.9 Market opportunity by Application
- Market opportunity by Application ($ million)
- Data Table on Market opportunity by Application ($ million)
11 Customer Landscape
- 11.1 Customer landscape overview
- Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
12 Geographic Landscape
- 12.1 Geographic segmentation
- Chart on Market share by geography 2023-2028 (%)
- Data Table on Market share by geography 2023-2028 (%)
- 12.2 Geographic comparison
- Chart on Geographic comparison
- Data Table on Geographic comparison
- 12.3 North America - Market size and forecast 2023-2028
- Chart on North America - Market size and forecast 2023-2028 ($ million)
- Data Table on North America - Market size and forecast 2023-2028 ($ million)
- Chart on North America - Year-over-year growth 2023-2028 (%)
- Data Table on North America - Year-over-year growth 2023-2028 (%)
- 12.4 Europe - Market size and forecast 2023-2028
- Chart on Europe - Market size and forecast 2023-2028 ($ million)
- Data Table on Europe - Market size and forecast 2023-2028 ($ million)
- Chart on Europe - Year-over-year growth 2023-2028 (%)
- Data Table on Europe - Year-over-year growth 2023-2028 (%)
- 12.5 Asia - Market size and forecast 2023-2028
- Chart on Asia - Market size and forecast 2023-2028 ($ million)
- Data Table on Asia - Market size and forecast 2023-2028 ($ million)
- Chart on Asia - Year-over-year growth 2023-2028 (%)
- Data Table on Asia - Year-over-year growth 2023-2028 (%)
- 12.6 Rest of World (ROW) - Market size and forecast 2023-2028
- Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
- Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
- Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
- Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
- 12.7 US - Market size and forecast 2023-2028
- Chart on US - Market size and forecast 2023-2028 ($ million)
- Data Table on US - Market size and forecast 2023-2028 ($ million)
- Chart on US - Year-over-year growth 2023-2028 (%)
- Data Table on US - Year-over-year growth 2023-2028 (%)
- 12.8 UK - Market size and forecast 2023-2028
- Chart on UK - Market size and forecast 2023-2028 ($ million)
- Data Table on UK - Market size and forecast 2023-2028 ($ million)
- Chart on UK - Year-over-year growth 2023-2028 (%)
- Data Table on UK - Year-over-year growth 2023-2028 (%)
- 12.9 China - Market size and forecast 2023-2028
- Chart on China - Market size and forecast 2023-2028 ($ million)
- Data Table on China - Market size and forecast 2023-2028 ($ million)
- Chart on China - Year-over-year growth 2023-2028 (%)
- Data Table on China - Year-over-year growth 2023-2028 (%)
- 12.10 Canada - Market size and forecast 2023-2028
- Chart on Canada - Market size and forecast 2023-2028 ($ million)
- Data Table on Canada - Market size and forecast 2023-2028 ($ million)
- Chart on Canada - Year-over-year growth 2023-2028 (%)
- Data Table on Canada - Year-over-year growth 2023-2028 (%)
- 12.11 Japan - Market size and forecast 2023-2028
- Chart on Japan - Market size and forecast 2023-2028 ($ million)
- Data Table on Japan - Market size and forecast 2023-2028 ($ million)
- Chart on Japan - Year-over-year growth 2023-2028 (%)
- Data Table on Japan - Year-over-year growth 2023-2028 (%)
- 12.12 Market opportunity by geography
- Market opportunity by geography ($ million)
- Data Tables on Market opportunity by geography ($ million)
- 12.13 Germany - Market size and forecast (2023-2028)
- Chart on Germany - Market size and forecast (2023-2028) ($ million)
- Data Table on Germany - Market size and forecast (2023-2028) ($ million)
- Chart on Germany - Year-over-year growth (2023-2028) (%)
- Data Table on Germany - Year-over-year growth (2023-2028) (%)
- 12.14 Italy - Market size and forecast (2023-2028)
- Chart on Italy - Market size and forecast (2023-2028) ($ million)
- Data Table on Italy - Market size and forecast (2023-2028) ($ million)
- Chart on Italy - Year-over-year growth (2023-2028) (%)
- Data Table on Italy - Year-over-year growth (2023-2028) (%)
- 12.15 France - Market size and forecast (2023-2028)
- Chart on France - Market size and forecast (2023-2028) ($ million)
- Data Table on France - Market size and forecast (2023-2028) ($ million)
- Chart on France - Year-over-year growth (2023-2028) (%)
- Data Table on France - Year-over-year growth (2023-2028) (%)
- 12.16 India - Market size and forecast (2023-2028)
- Chart on India - Market size and forecast (2023-2028) ($ million)
- Data Table on India - Market size and forecast (2023-2028) ($ million)
- Chart on India - Year-over-year growth (2023-2028) (%)
- Data Table on India - Year-over-year growth (2023-2028) (%)
- 12.17 Brazil - Market size and forecast (2023-2028)
- Chart on Brazil - Market size and forecast (2023-2028) ($ million)
- Data Table on Brazil - Market size and forecast (2023-2028) ($ million)
- Chart on Brazil - Year-over-year growth (2023-2028) (%)
- Data Table on Brazil - Year-over-year growth (2023-2028) (%)
- 12.18 Egypt - Market size and forecast (2023-2028)
- Chart on Egypt - Market size and forecast (2023-2028) ($ million)
- Data Table on Egypt - Market size and forecast (2023-2028) ($ million)
- Chart on Egypt - Year-over-year growth (2023-2028) (%)
- Data Table on Egypt - Year-over-year growth (2023-2028) (%)
- 12.19 UAE - Market size and forecast (2023-2028)
- Chart on UAE - Market size and forecast (2023-2028) ($ million)
- Data Table on UAE - Market size and forecast (2023-2028) ($ million)
- Chart on UAE - Year-over-year growth (2023-2028) (%)
- Data Table on UAE - Year-over-year growth (2023-2028) (%)
- 12.20 Oman - Market size and forecast (2023-2028)
- Chart on Oman - Market size and forecast (2023-2028) ($ million)
- Data Table on Oman - Market size and forecast (2023-2028) ($ million)
- Chart on Oman - Year-over-year growth (2023-2028) (%)
- Data Table on Oman - Year-over-year growth (2023-2028) (%)
- 12.21 Argentina - Market size and forecast (2023-2028)
- Chart on Argentina - Market size and forecast (2023-2028) ($ million)
- Data Table on Argentina - Market size and forecast (2023-2028) ($ million)
- Chart on Argentina - Year-over-year growth (2023-2028) (%)
- Data Table on Argentina - Year-over-year growth (2023-2028) (%)
- 12.22 KSA - Market size and forecast (2023-2028)
- Chart on KSA - Market size and forecast (2023-2028) ($ million)
- Data Table on KSA - Market size and forecast (2023-2028) ($ million)
- Chart on KSA - Year-over-year growth (2023-2028) (%)
- Data Table on KSA - Year-over-year growth (2023-2028) (%)
13 Drivers, Challenges, and Opportunity/Restraints
- 13.3 Impact of drivers and challenges
- Impact of drivers and challenges in 2023 and 2028
- 13.4 Market opportunities/restraints
14 Competitive Landscape
- 14.2 Competitive Landscape
- Overview on criticality of inputs and factors of differentiation
- 14.3 Landscape disruption
- Overview on factors of disruption
- 14.4 Industry risks
- Impact of key risks on business
15 Competitive Analysis
- 15.2 Market positioning of companies
- Matrix on companies position and classification
- 15.3 Astellas Pharma Inc.
- Astellas Pharma Inc. - Overview
- Astellas Pharma Inc. - Product / Service
- Astellas Pharma Inc. - Key offerings
- 15.4 bluebird bio, Inc.
- bluebird bio, Inc. - Overview
- bluebird bio, Inc. - Product / Service
- bluebird bio, Inc. - Key offerings
- 15.5 CRISPR Therapeutics AG
- CRISPR Therapeutics AG - Overview
- CRISPR Therapeutics AG - Product / Service
- CRISPR Therapeutics AG - Key offerings
- 15.6 Gilead Sciences, Inc.
- Gilead Sciences, Inc. - Overview
- Gilead Sciences, Inc. - Product / Service
- Gilead Sciences, Inc. - Key offerings
- 15.7 Kite Pharma (Gilead Sciences)
- Kite Pharma (Gilead Sciences) - Overview
- Kite Pharma (Gilead Sciences) - Product / Service
- Kite Pharma (Gilead Sciences) - Key offerings
- 15.8 Novartis AG
- Novartis AG - Overview
- Novartis AG - Product / Service
- Novartis AG - Key offerings
- 15.9 Orchard Therapeutics plc
- Orchard Therapeutics plc - Overview
- Orchard Therapeutics plc - Product / Service
- Orchard Therapeutics plc - Key offerings
- 15.10 Pfizer Inc.
- Pfizer Inc. - Overview
- Pfizer Inc. - Product / Service
- Pfizer Inc. - Key offerings
- 15.11 RegenXBio Inc.
- RegenXBio Inc. - Overview
- RegenXBio Inc. - Product / Service
- RegenXBio Inc. - Key offerings
- 15.12 Roche Holding AG
- Roche Holding AG - Overview
- Roche Holding AG - Product / Service
- Roche Holding AG - Key offerings
- 15.13 Sarepta Therapeutics, Inc.
- Sarepta Therapeutics, Inc. - Overview
- Sarepta Therapeutics, Inc. - Product / Service
- Sarepta Therapeutics, Inc. - Key offerings
- 15.14 Spark Therapeutics (Roche)
- Spark Therapeutics (Roche) - Overview
- Spark Therapeutics (Roche) - Product / Service
- Spark Therapeutics (Roche) - Key offerings
- 15.15 uniQure N.V.
- uniQure N.V. - Overview
- uniQure N.V. - Product / Service
- uniQure N.V. - Key offerings
- 15.16 Voyager Therapeutics, Inc.
- Voyager Therapeutics, Inc. - Overview
- Voyager Therapeutics, Inc. - Product / Service
- Voyager Therapeutics, Inc. - Key offerings
- 15.17 VBL Therapeutics
- VBL Therapeutics - Overview
- VBL Therapeutics - Product / Service
- VBL Therapeutics - Key offerings
- 15.18 Vertex Pharmaceuticals Incorporated
- Vertex Pharmaceuticals Incorporated - Overview
- Vertex Pharmaceuticals Incorporated - Product / Service
- Vertex Pharmaceuticals Incorporated - Key offerings
- 15.19 Xencor, Inc.
- Xencor, Inc. - Overview
- Xencor, Inc. - Product / Service
- Xencor, Inc. - Key offerings
- 15.20 Sangamo Therapeutics, Inc.
- Sangamo Therapeutics, Inc. - Overview
- Sangamo Therapeutics, Inc. - Product / Service
- Sangamo Therapeutics, Inc. - Key offerings
- 15.21 Amgen Inc.
- Amgen Inc. - Overview
- Amgen Inc. - Product / Service
- Amgen Inc. - Key offerings
- 15.22 Biogen Inc.
- Biogen Inc. - Overview
- Biogen Inc. - Product / Service
- Biogen Inc. - Key offerings
- 15.23 Abeona Therapeutics Inc
- Abeona Therapeutics Inc - Overview
- Abeona Therapeutics Inc - Product / Service
- Abeona Therapeutics Inc - Key offerings
- 15.24 Adaptimmune Therapeutics plc
- Adaptimmune Therapeutics plc - Overview
- Adaptimmune Therapeutics plc - Product / Service
- Adaptimmune Therapeutics plc - Key offerings
- 15.25 Adverum Biotechnologies Inc
- Adverum Biotechnologies Inc - Overview
- Adverum Biotechnologies Inc - Product / Service
- Adverum Biotechnologies Inc - Key offerings
- 15.26 Amgen Inc.
- Amgen Inc. - Overview
- Amgen Inc. - Product / Service
- Amgen Inc. - Key offerings
- 15.27 Astellas Pharma Inc.
- Astellas Pharma Inc. - Overview
- Astellas Pharma Inc. - Product / Service
- Astellas Pharma Inc. - Key offerings
- 15.28 Biogen Inc.
- Biogen Inc. - Overview
- Biogen Inc. - Product / Service
- Biogen Inc. - Key offerings
- 15.29 bluebird bio Inc.
- bluebird bio Inc. - Overview
- bluebird bio Inc. - Product / Service
- bluebird bio Inc. - Key offerings
- 15.30 Editas Medicine Inc.
- Editas Medicine Inc. - Overview
- Editas Medicine Inc. - Product / Service
- Editas Medicine Inc. - Key offerings
- 15.31 ElevateBio
- ElevateBio - Overview
- ElevateBio - Product / Service
- ElevateBio - Key offerings
- 15.32 F. Hoffmann La Roche Ltd.
- F. Hoffmann La Roche Ltd. - Overview
- F. Hoffmann La Roche Ltd. - Product / Service
- F. Hoffmann La Roche Ltd. - Key offerings
- 15.33 Generation Bio Co.
- Generation Bio Co. - Overview
- Generation Bio Co. - Product / Service
- Generation Bio Co. - Key offerings
- 15.34 Gilead Sciences Inc.
- Gilead Sciences Inc. - Overview
- Gilead Sciences Inc. - Product / Service
- Gilead Sciences Inc. - Key offerings
- 15.35 Novartis AG
- Novartis AG - Overview
- Novartis AG - Product / Service
- Novartis AG - Key offerings
- 15.36 Orchard Therapeutics Plc
- Orchard Therapeutics Plc - Overview
- Orchard Therapeutics Plc - Product / Service
- Orchard Therapeutics Plc - Key offerings
- 15.37 Poseida Therapeutics Inc.
- Poseida Therapeutics Inc. - Overview
- Poseida Therapeutics Inc. - Product / Service
- Poseida Therapeutics Inc. - Key offerings
- 15.38 Sangamo Therapeutics Inc
- Sangamo Therapeutics Inc - Overview
- Sangamo Therapeutics Inc - Product / Service
- Sangamo Therapeutics Inc - Key offerings
- 15.39 Sibiono GeneTech Co. Ltd.
- Sibiono GeneTech Co. Ltd. - Overview
- Sibiono GeneTech Co. Ltd. - Product / Service
- Sibiono GeneTech Co. Ltd. - Key offerings
- 15.40 Syncona Ltd.
- Syncona Ltd. - Overview
- Syncona Ltd. - Product / Service
- Syncona Ltd. - Key offerings
- 15.41 uniQure NV
- uniQure NV - Overview
- uniQure NV - Product / Service
- uniQure NV - Key offerings
- 15.42 Voyager Therapeutics Inc
- Voyager Therapeutics Inc - Overview
- Voyager Therapeutics Inc - Product / Service
- Voyager Therapeutics Inc - Key offerings
16 Appendix
- 16.2 Inclusions and exclusions checklist
- Inclusions checklist
- Exclusions checklist
- 16.3 Currency conversion rates for US$
- Currency conversion rates for US$
- 16.4 Research methodology
- 16.7 Validation techniques employed for market sizing
- Validation techniques employed for market sizing
- 16.9 360 degree market analysis
- 360 degree market analysis
- 16.10 List of abbreviations
INFORMATION SOURCES
DATA ANALYSIS
REPORT WRITING
Get the report (PDF) sent to your email within minutes.
Complimentary full Excel data with your report purchase.
